Eli lilly
Pharma
Also written as: Lilly, Mounjaro, Verzenio, Zepbound
Data as of 4 Oct 2026
Markdown version
Markdown version
Eli lilly was mentioned 130 times in 59 outlets across 11 countries over the last 12 months. 54% of that coverage was positive and 4% negative. 93% was editorial rather than PR or paid placement.
MENTIONS · 12M
130
135 all-time
OUTLETS · 12M
59
in 11 countries
AVG SENTIMENT
+0.363
EDITORIAL
93%
9 PR · 121 editorial
Recent coverage
Lilly's $2.88 Billion Immunology Deal Starts in Phase 1 - GuruFocus
gurufocus.com · INT · 1 Sep 2026 · neutral
Eli Lilly’s diabetes drug Mounjaro approved to reduce cardiovascular risks - Business Today
businesstoday.in · IN · 1 Sep 2026 · positive
Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong? - Yahoo Finance
finance.yahoo.com · INT · 31 Aug 2026 · positive
Eli Lilly (NYSE:LLY) Gains As Metabolic Health Demand Grows - Kalkine Media
kalkinemedia.com · INT · 31 Aug 2026 · positive
Mounjaro Approved to Reduce Cardiovascular Risk in Type 2 Diabetes - docwirenews.com
docwirenews.com · INT · 31 Aug 2026 · positive
Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors. - The Motley Fool
fool.com · INT · 31 Aug 2026 · positive
Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’ - Stocktwits
stocktwits.com · INT · 31 Aug 2026 · neutral
Breadth Narrows, Software Shines; Fortinet, Edwards Lifesciences, UBS In Focus - Investor's Business Daily
investors.com · INT · 31 Aug 2026 · positive
Coverage over time · mentions per month
Mentions per month as a table
| Month | Mentions |
|---|---|
| 2025-11 | 0 |
| 2025-12 | 0 |
| 2026-01 | 1 |
| 2026-02 | 0 |
| 2026-03 | 0 |
| 2026-04 | 0 |
| 2026-05 | 2 |
| 2026-06 | 21 |
| 2026-07 | 2 |
| 2026-08 | 102 |
| 2026-09 | 2 |
| 2026-10 | 0 |
Share of voice among Pharma peers · 12m
| Brand | Mentions | Share |
|---|---|---|
| Eli lilly | 130 | 23% |
| Astrazeneca | 78 | 14% |
| Pfizer | 64 | 11% |
| Johnson & johnson | 59 | 10% |
| Novo nordisk | 46 | 8% |
| Merck | 44 | 8% |
| Sandoz | 41 | 7% |
| Moderna | 38 | 7% |
| Bayer | 36 | 6% |
| Roche | 36 | 6% |
Track Eli lilly against its rivals
Daily mentions, sentiment, share of voice and alerts — only what is actually about the brand.
Start trackingIs this your brand?
Claim the page to correct aliases, website or sector, and see the full picture.
Claim this page